Why Medtech Companies Should Implement Regionalized Sales Models
In today’s dynamic healthcare environment, IDN consolidation and centralized medical device purchasing are creating significant pricing pressure on the medical device industry. In fact, on average, prices for costly medical devices have been declining recently, according to the Emergency Care Research Institute. Medtech business leaders, therefore, have to work to find ways to evolve and grow earnings in this highly competitive and challenging environment.
2017 Value Watch List in US Oncology Market
As part of the ZS Oncology Value Watchdog Initiative, we have identified priority areas for manufacturers to consider as some of the most influential drivers of value-driven cancer care in the US in 2017.
“Value” within healthcare is a complex, abstract concept that can take on many forms. The Healthcare Leadership Council (HLC), a coalition of chief executives and other thought leaders across the healthcare industry—including ZS—has been building consensus on the best ways to deliver value through its National Dialogue for Healthcare Innovation initiative (NDHI).
Ready for an Agile Future
A top-20 pharmaceutical company partnered with ZS to reduce cycle times by 40%, costs by 20%, and to solve a field reporting problem with a mobile, one-stop-shop solution that gives the field more time to sell.
The Digital Enterprise in Action
Amgen’s awardwinning data lake revolutionized the company’s global operations by driving bottom-line savings and enabling new data-driven insights—and, as a bonus, it offered the same potential to the entire company.
A Customer-Centric Approach to Promotion Planning
As the global healthcare landscape continues to evolve, many biopharmaceutical companies continue to deploy a scattered, mass-market approach to targeting healthcare providers through a wide variety of channels and tactics.
Navigating the Dotted Line
Transforming pricing and contract management practices often appears to be easier said than done, but it’s worth the effort—and it’s achievable. Read this article to learn how to get started.
Pharma Biotech IPR Infographic 2016
Tailoring effective incentive compensation plans can be tough in all therapeutic areas, but oncology presents even more of a challenge given its extremely complicated market with frequent changes, small patient populations, low sales volume and products that are used across multiple indications.
Prescriptions in Prime Time
As the U.S. healthcare landscape continues to evolve and as consumers’ media consumption behaviors undergo significant changes, many pharmaceutical brands are continuing to invest in direct-to-consumer advertising—especially TV.
Displaying 1 - 15 of 465